Clinical Trial

China’s Original HER2 ADC Botuzumab (Shutai Lai®) Prescriptions Launched, Opening a New Chapter in HER2 Positive Breast Cancer Treatment

by
China's Original HER2 ADC Botuzumab (Shutai Lai®) Prescriptions Launched, Opening a New Chapter in HER2 Positive Breast Cancer Treatment

Introduction The field of anti-tumor treatment in China has reached a significant milestone—the first domestically developed HER2 antibody-drug conjugate (ADC) Botuzumab (Shutai Lai®) for the treatment of HER2 positive breast cancer, which can be widely used in second-line and above therapies, has been prescribed in multiple top hospitals across the country.This marks the official entry … Read more

AstraZeneca Registers Phase III Clinical Trial for B7-H4 ADC, Hansoh/GSK Leads, Pfizer Halts Development

by
AstraZeneca Registers Phase III Clinical Trial for B7-H4 ADC, Hansoh/GSK Leads, Pfizer Halts Development

On November 17, 2025, the drug clinical trial registration and information disclosure platform showed that AstraZeneca registered the B7-H4 ADC Puxitatug Samrotecan (P-Sam, AZD8205) in a single-agent controlled physician’s choice chemotherapy treatment for patients with advanced/metastatic endometrial cancer (EC) that selectively expresses B7-H4 (≥25% tumor cell expression) and has progressed during or after platinum-based chemotherapy … Read more

Professor Shen Lin’s Team Tackles Gastric Cancer! CLDN18.2 Targeted ADC Drug IBI343 Phase I Study Tops Nature Medicine

by
Professor Shen Lin's Team Tackles Gastric Cancer! CLDN18.2 Targeted ADC Drug IBI343 Phase I Study Tops Nature Medicine

Professor Shen Lin’s team tackles gastric cancer! The CLDN18.2 targeted ADC drug IBI343 Phase I study tops Nature Medicine. Gastric cancer, as a “health killer” globally, is particularly rampant in East Asia. Data shows that in 2022, there were 358,700 new cases of gastric cancer in China, with 260,400 deaths, accounting for nearly 40% of … Read more

Phase I Clinical Trial of New CoupidCAR Therapy GCC19CART for Refractory Solid Tumors

by
Phase I Clinical Trial of New CoupidCAR Therapy GCC19CART for Refractory Solid Tumors

Click the blue text above to follow for more exciting content What is CAR-T Cell Therapy? CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a type of immunotherapy primarily used for the clinical treatment of malignant blood diseases and tumors. CAR-T therapy involves collecting and isolating T cells from the patient’s blood, followed by genetic … Read more

ESC 2024: PROTEUS Study on AI in Stress Echocardiography

by
ESC 2024: PROTEUS Study on AI in Stress Echocardiography

*This material is for healthcare professionals only and should not be distributed to non-healthcare professionals. From August 30 to September 2, 2024, the European Society of Cardiology Annual Congress (ESC 2024) will be held in London, UK, and online globally. During the HOT LINE 12 session, Professor Ross Upton from the University of Oxford will … Read more

MULTISTARS AMI Trial Shows Immediate vs. Staged Revascularization in STEMI Patients

by
MULTISTARS AMI Trial Shows Immediate vs. Staged Revascularization in STEMI Patients

In patients with ST-segment elevation myocardial infarction (STEMI), approximately 50% have multivessel coronary artery disease, which is associated with an increased risk of recurrent myocardial infarction and death. The COMPLETE trial indicated that complete revascularization in patients with STEMI and multivessel coronary artery disease is superior to percutaneous coronary intervention (PCI) that only opens the … Read more

China’s Strong Voice | New Achievements in Anti-CLDN18.2 ADC, Latest Research Results of IBI343 Revealed

by
China's Strong Voice | New Achievements in Anti-CLDN18.2 ADC, Latest Research Results of IBI343 Revealed

Introduction Gastric cancer remains a significant public health challenge globally, ranking fifth in incidence and mortality among all cancer types. In recent years, targeted therapy and immunotherapy have greatly improved survival for patients with gastric cancer/gastroesophageal junction cancer (GC/GEJC). However, there are few meaningful therapeutic targets in the field of gastric cancer, and the benefits … Read more

Phase II RCT of New ADC Brings Hope for R/R DLBCL Treatment

by
Phase II RCT of New ADC Brings Hope for R/R DLBCL Treatment

From May 30 to June 3, 2025, the largest global oncology conference, the American Society of Clinical Oncology (ASCO) Annual Meeting, was held in Chicago, USA. Researchers including Philippe Armand presented data from the waveLINE-003 Phase II study, exploring the recommended treatment dose, safety, and efficacy of the novel antibody-drug conjugate (ADC) Zilovertamab vedotin (ZV) … Read more

New Explorations in High-Risk AML Treatment: AZA Combined with HiDAC / Mito Regimen

by
New Explorations in High-Risk AML Treatment: AZA Combined with HiDAC / Mito Regimen

Acute myeloid leukemia (AML) has a generally poor prognosis, with a 5-year survival rate of approximately 27%. Some subgroup studies indicate that patients with treatment-related AML (t-AML), older AML patients (aged ≥60 years), relapsed/refractory AML (R/R-AML) patients, and those who develop AML from other hematological diseases have worse prognostic outcomes. In high-risk AML patients, the … Read more

The First PROTAC DAC (ABBV-787) Clinical Trial Termination: Unveiling the Truth

by
The First PROTAC DAC (ABBV-787) Clinical Trial Termination: Unveiling the Truth

Following a series of DAC transactions last year, interest in this area has gradually increased, leading to various discussions and reviews. Among the products in the clinical phase of DAC, AbbVie‘s product ABBV-787 frequently appears alongside ORM-5029 and ORM-6151, but unlike the latter two, ABBV-787 has never disclosed any technical details in public forums. Although … Read more